WHO Collaborating Centre for Viral Hepatitis, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Department of Medicine (RMH), University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Intern Med J. 2021 Jun;51(6):910-922. doi: 10.1111/imj.15069.
Aboriginal and Torres Strait Islander people are disproportionately affected by hepatitis B virus (HBV) infection. A proposed mismatch between standard vaccines and the HBV/C4 sub-genotype prevalent in Aboriginal people in the Northern Territory (NT) may reduce vaccine effectiveness.
To determine HBV prevalence in the NT by Indigenous status and to explore patterns of immunity following implementation of universal vaccination, using a large longitudinal diagnostic dataset.
A retrospective analysis of all available HBV serology results in the NT from 1991 to 2011 was conducted, with HBV prevalence and vaccination status analysed according to adigenous status, age and sex using individuals' patterns of HBsAg, anti-HBs and anti-HBc serology over repeated tests.
100 790 individuals were tested (33.4% Indigenous) between 1991 and 2011 (26.1% of the 2011 NT population), with a total of 211 802 tests performed. In 2011, the proportion of HBV positive individuals in the NT was 3.17% (5.22% in Indigenous populations) compared to previous 2011 estimates of 1.70% (3.70% in Indigenous populations). The vaccine failure rate was lower than expected with only one presumed vaccinated person subsequently developing HBsAg positivity (0.02%). Evidence of suboptimal vaccine efficacy by breakthrough anti-HBc positivity in vaccinated individuals was demonstrated in 3.1% of the vaccinated cohort, of which 86.4% identified as Indigenous (HR 1.17). No difference in HBeAg positivity or seroconversion was observed between Indigenous and non-Indigenous individuals living with CHB.
The burden of CHB in Indigenous people in the NT has previously been underestimated. A higher HBV prevalence in the NT than described in previous cross-sectional studies was found, including a higher prevalence in Indigenous people. Evidence of suboptimal vaccine efficacy was demonstrated predominantly in Indigenous individuals.
原住民和托雷斯海峡岛民受乙型肝炎病毒(HBV)感染的影响不成比例。在北领地(NT),标准疫苗与流行的 HBV/C4 亚基因型之间可能存在不匹配,这可能会降低疫苗的有效性。
通过原住民身份确定 NT 中的 HBV 流行情况,并利用大型纵向诊断数据集探索普遍接种疫苗后的免疫模式。
对 1991 年至 2011 年 NT 中所有可用的 HBV 血清学结果进行回顾性分析,根据个体在重复检测中 HBsAg、抗-HBs 和抗-HBc 血清学的模式,按原住民身份、年龄和性别分析 HBV 流行情况和疫苗接种状况。
1991 年至 2011 年期间共检测了 100790 人(33.4%为原住民)(占 2011 年 NT 人口的 26.1%),共进行了 211802 次检测。2011 年,NT 中 HBV 阳性个体的比例为 3.17%(原住民人群中为 5.22%),而之前 2011 年的估计值为 1.70%(原住民人群中为 3.70%)。疫苗失败率低于预期,仅有一名假定接种疫苗的人随后出现 HBsAg 阳性(0.02%)。在接种疫苗的队列中,有 3.1%的人出现突破性抗-HBc 阳性,表明疫苗效力不足,其中 86.4%为原住民(HR 1.17)。在携带 CHB 的人群中,未观察到 HBeAg 阳性或血清转换率在原住民和非原住民之间存在差异。
NT 原住民中 CHB 的负担以前被低估了。与之前的横断面研究相比,NT 中的 HBV 流行率更高,包括原住民中的流行率更高。主要在原住民中发现了疫苗效力不足的证据。